“High-quality randomized trials, cohort studies, and Mendelian randomization consistently show that cardiometabolic risk is cumulative and multifactorial; interventions acting on different causal pathways produce additive, not competing, benefits. Lifestyle modification remains foundational, yet its effect sizes, while meaningful, in certain patients may not achieve the magnitude or durability seen with therapies targeting specific biological drivers of disease such as LDL-mediated atherogenesis.
Conversely, pharmacologic therapy without lifestyle optimization leaves substantial modifiable risk unaddressed. Modern prevention frameworks and guidelines explicitly integrate both domains because the totality of evidence demonstrates that outcomes improve most when nutrition, physical activity, weight management, and smoking cessation are paired with therapies proven to reduce hard end points.”
Link to original post:



